Arie Belldegrun (Photo: Jeff Rumans for Endpoints News)
April 12, 2020 01:57 PM EDT
R&D

Judge slaps en­hanced dam­ages on Gilead/Kite for ‘will­ful’ patent vi­o­la­tion, boost­ing award to a block­buster $1.2B — with the me­ter run­ning

John Carroll

Editor & Founder

The Gilead/Kite team has suf­fered the lat­est in a se­ries of set­backs in its war with Bris­tol My­ers Squibb sub­sidiary Juno and Memo­r­i­al Sloan Ket­ter­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times